SEQUENCE LISTING

- - V

```
<110> Quinn, Conrad P
       Foster, Keith A
       Chaddock, John A
<120> Methods and Compounds for the Treatment of Mucus Hypersecretion
<130> 1581.0770001
<150> 09/763,669
<151> 1999-08-25
<150> PCT/GB99/02806
<151> 1999-08-25
<150> GB 9818548.1
<151> 1998-08-25
<160> 8
<170> PatentIn version 3.2
<210> 1
<211> 23
<212> PRT
<213> Influenza virus
<400> 1
Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu Gly
Met Ile Asp Gly Trp Tyr Gly
            20
<210> 2
<211> 12
<212> PRT
<213> Substance P peptide sequence
<400> 2
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met Cys
<210> 3
<211> 12
<212> PRT
<213> Substance P peptide sequence with N-terminal Cys
<400> 3
Cys Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met
<210> 4
```

```
<211> 4
<212> PRT
<213> Factor Xa
<220>
<221> MISC FEATURE
<222> (4)..(4)
<223> specific cleavable peptide bond
<400> 4
Ile Glu Gly Arg
<210> 5
<211> 5
<212> PRT
<213> Enterokinase
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> specific cleavable peptide bond
<400> 5
Asp Asp Asp Lys
<210> 6
<211> 8
<212> PRT
<213> TEV protease
<220>
<221> misc_feature
<222> (2)..(3)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> MISC_FEATURE
<222> (7)..(8)
<223> specific cleavable peptide bond
<400> 6
Glu Xaa Xaa Tyr Xaa Gln Ser Gly
<210> 7
```

... "

```
<211> 8
<212> PRT
<213> Precission

<220>
<221> MISC_FEATURE
<222> (6)...(7)
<223> specific cleavable peptide bond
<400> 7

Leu Glu Val Leu Phe Gln Gly Pro
1 5

<210> 8
<211> 6
<212> PRT
<213> Thrombin

<220>
<221> MISC_FEATURE
<222> (4)...(5)
<221> Specific cleavable peptide bond
<400 8

Leu Val Pro Arg Gly Ser
1 5
```

- T